Requires hepatic bioactivation to an active thiol metabolite that irreversibly binds platelet P2Y12 receptors, inhibiting ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation.
Indications / reported uses
Prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischaemic stroke or established peripheral arterial disease
Acute coronary syndrome, including non-ST-elevation and ST-elevation myocardial infarction, in combination with aspirin under the applicable label
Prevention of stent thrombosis after percutaneous coronary intervention as part of dual antiplatelet therapy; duration is patient- and product-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Clopidogrel Environmental Risk Assessment (ERA) (the Clopidogrel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.